Indivior Raises CEO and CFO Base Salaries for 2026

Indivior plc has announced salary increases for its CEO and CFO, effective January 1, 2026. CEO Joseph Ciaffoni's salary will rise from $1,050,000 to $1,115,000, and CFO Ryan Preblick's salary will increase from $559,000 to $604,000. These adjustments follow a market review and recommendations from the company's Compensation Committee.

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations | INDV Stock News

Indivior PLC announced results from a clinical trial showing that extended-release buprenorphine (SUBLOCADE®) in 100 mg and 300 mg doses significantly reduces opioid use and supports abstinence in high-risk populations. The 300 mg dose was particularly effective for individuals with high-frequency fentanyl use. Both doses were well-tolerated with no new safety concerns. Injection-site reactions were more common with the 300 mg dose but were mild to moderate. The study highlights the need for adaptable treatment approaches for opioid use disorder (OUD).

Indivior plc Held Shareholder Meeting on Scheme of Arrangement

Indivior plc held shareholder meetings on December 11, 2025, to vote on the Scheme of Arrangement. Shareholders approved proposals to authorize directors to implement the scheme, reduce share capital, and issue new shares. This information was published by Indivior plc via the EDGAR system.

Indivior shares are trading higher after the company was added to the S&P SmallCap 600.

Indivior (INDV) Is Up 6.5% After Settling DOJ Liability and Ending Resolution Agreement – Has The Bull Case Changed?

Indivior PLC settled a $295 million liability with the U.S. DOJ, ending a resolution agreement and simplifying its capital structure. This milestone removes a major legal overhang, potentially influencing its investment narrative and risk profile. Despite improved net income and revenue outlook, Indivior's high earnings multiples and debt remain concerns. Fair value estimates vary widely, reflecting differing market expectations. The settlement marks a turning point, but investors should remain cautious of ongoing risks.